The University of Arizona and pharmaceutical company Sunshine Biopharma are developing medical technology to minimize the ...
In a recent study posted to the bioRxiv* pre-print server, a team of researchers discovered S-217622, a non-covalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease ...
FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...
A large systematic review on pregnant women living with HIV found that protease inhibitor–based antiretroviral therapy (ART) use was associated with increased risk of babies being born small or very ...
In a recent study posted to the Research Square preprint* server, a team of researchers investigated the toxicity and absorption, distribution, metabolism, and excretion (ADME) characteristics of a ...
Sunshine Biopharma (SBFM) has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity in ...
**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April). Please credit the conference if you ...
HIV-1 protease inhibitors (PIs) have long been central to antiretroviral therapy, directly targeting the enzyme responsible for processing viral polyproteins into functional units. Their efficacy, ...
HIV-1 protease inhibitors are unique among anti-HIV-1 drugs in that they have very high potency and they also have a very high genetic barrier to resistance. The viral protease is essential in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback